Grifols, S.A. (GIFLF)
| Previous close | 11.76 |
| Open | 11.76 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 11.76 - 11.76 |
| 52-week range | 7.90 - 21.00 |
| Volume | |
| Avg. volume | 648 |
| Market cap | 5.852B |
| Beta (5Y monthly) | 0.45 |
| PE ratio (TTM) | 35.64 |
| EPS (TTM) | 0.33 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 03 June 2021 |
| 1y target est | N/A |
- Zacks
Are Investors Undervaluing Grifols (GRFS) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Zacks
Grifols (GRFS) Upgraded to Strong Buy: Here's Why
Grifols (GRFS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- PR Newswire
Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease
Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced today that it has entered into a research, development and sublicense agreement with Grifols (Nasdaq: GRFS), a global leader in plasma-derived medicines, for the development and commercialization of immunoglobulin eye drops for dry eye disease.
